入院时尿液和血清代谢物可预测肝硬化住院患者的肾脏结局
本研究纳入北美11个终末期肝病中心602例提供血清、435例提供尿液的肝硬化住院患者,采用代谢组学分析发现入院时特定血清和尿液代谢物在临床变量基础上可显著提高对急性肾损伤(AKI)发生和透析启动的预测能力,血清预测AKI的校正AUC为0.91,尿液为0.88。
要点
- 入院血清和尿液代谢物在临床变量基础上可显著提高肝硬化住院患者AKI和透析的预测。
- 血清预测AKI的临床因素校正AUC为0.91,尿液为0.88;预测透析分别为0.93和0.91。
- 尿毒症毒素和色氨酸/酪氨酸代谢物在发生AKI的患者中升高。
核心结论
- 特定入院尿液和血清代谢物在临床变量基础上可显著提高对肝硬化住院患者AKI发生和透析启动的预测。
研究设计与样本
- 来自北美11个终末期肝病联盟中心的肝硬化住院患者,入院时无AKI且未透析者提供血清/尿液。
- 602例提供血清(218例发生AKI,80例需要透析),435例提供尿液(164例发生AKI,61例需要透析)。
- 采用协方差分析校正人口学、感染和肝硬化严重程度,以随机森林和AUC分析识别与结局相关的代谢物,并进行逻辑回归。
主要发现
- 预测AKI的临床因素校正AUC:血清0.91,尿液0.88。
- 预测透析的临床因素校正AUC:血清0.93,尿液0.91。
- 在AKI患者中预测透析的AUC:血清0.81,尿液0.79。
- 发生AKI的患者中尿毒症毒素(DMTPA、N2N2二甲基鸟苷、尿苷/假尿苷)和色氨酸/酪氨酸代谢物(犬尿氨酸、8-甲氧基犬尿氨酸、喹啉酸)较高。
- AKI需要透析的患者中支链氨基酸代谢物较低,而半胱氨酸、色氨酸、谷氨酸和DMTPA较高。
关键数值与推荐
- 预测AKI:血清临床因素校正AUC 0.91,尿液0.88。
- 预测透析:血清临床因素校正AUC 0.93,尿液0.91。
- AKI患者中预测透析:血清AUC 0.81,尿液0.79。
临床怎么用
- 入院血清/尿液代谢物可在临床变量基础上辅助早期识别肝硬化住院患者AKI和透析高风险者。
- 上述观察可能有助于更早启动肾脏保护措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Acute kidney injury (AKI) has a poor prognosis in cirrhosis. Given the variability of creatinine, the prediction of AKI and dialysis by other markers is needed. The aim of this study is to determine the role of serum and urine metabolomics in the prediction of AKI and dialysis in an inpatient cirrhosis cohort. APPROACH AND RESULTS: Inpatients with cirrhosis from 11 North American Consortium of End-stage Liver Disease centers who provided admission serum/urine when they were AKI and dialysis-free were included. Analysis of covariance adjusted for demographics, infection, and cirrhosis severity was performed to identify metabolites that differed among patients (1) who developed AKI or not; (2) required dialysis or not; and/pr (3) within AKI subgroups who needed dialysis or not. We performed random forest and AUC analyses to identify specific metabolite(s) associated with outcomes. Logistic regression with clinical variables with/without metabolites was performed. A total of 602 patients gave serum (218 developed AKI, 80 needed dialysis) and 435 gave urine (164 developed AKI, 61 needed dialysis). For AKI prediction, clinical factor-adjusted AUC was 0.91 for serum and 0.88 for urine. Major metabolites such as uremic toxins (2,3-dihydroxy-5-methylthio-4-pentenoic acid [DMTPA], N2N2dimethylguanosine, uridine/pseudouridine) and tryptophan/tyrosine metabolites (kynunerate, 8-methoxykyunerate, quinolinate) were higher in patients who developed AKI. For dialysis prediction, clinical factor-adjusted AUC was 0.93 for serum and 0.91 for urine. Similar metabolites as AKI were altered here. For dialysis prediction in those with AKI, the AUC was 0.81 and 0.79 for serum/urine. Lower branched-chain amino-acid (BCAA) metabolites but higher cysteine, tryptophan, glutamate, and DMTPA were seen in patients with AKI needing dialysis. Serum/urine metabolites were additive to clinical variables for all outcomes. CONCLUSIONS: Specific admission urinary and serum metabolites were significantly additive to clinical variables to predict AKI development and dialysis initiation in inpatients with cirrhosis. These observations can potentially facilitate earlier initiation of renoprotective measures.
引用
- Bajaj JS, Garcia-Tsao G, Reddy KR, et al. Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis. Hepatology. 2021. PMID: 34002868. doi:10.1002/hep.31907
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。